1 A loss-of-function *CCR*² variant is associated with lower cardiovascular risk

2

3 Marios K. Georgakis, MD, PhD^{*1-3}, Rainer Malik, PhD^{*1}, Omar El Bounkari, PhD¹, Natalie R. Hasbani, MPH⁴, Jiang Li MD, PhD⁵, Jennifer E. Huffman, PhD⁶, Gabrielle Shakt^{7,8}, Reinier W. P. 4 5 Tack, MD^{2,9}, Tamara N. Kimball, MD^{2,10}, Yaw Asare, PhD¹, Alanna C. Morrison, PhD⁴, BS, Noah L. Tsao, BS^{7,8}, Renae Judy, MS^{7,8}, Braxton D. Mitchell, PhD^{11,12}, Huichun Xu, MD, PhD¹¹, May E. 6 7 Montasser, PhD¹¹, Ron Do, PhD^{13,14}, Eimear E. Kenny^{13,15-17}, Ruth J.F. Loos, PhD¹³, James G. 8 Terry, MS¹⁸, John Jeffrey Carr, MD¹⁸, Joshua C. Bis, PhD¹⁹, Bruce M. Psaty, MD, PhD¹⁹⁻²¹, W. T. Longstreth, MD, MPH^{21,22}, Kendra A Young, MSPH, PhD²³, Sharon M Lutz, PhD^{24,25}, Michael H 9 Cho, MD, MPH²⁶, Jai Broome, BA²⁷, Alyna T. Khan²⁷, Fei Fei Wang, BS²⁷, Nancy Heard-Costa, 10 PhD^{28,29}, Sudha Seshadri, MD³⁰, Ramachandran S. Vasan, MD^{28,29,31}, Nicholette D. Palmer, 11 PhD³², Barry I. Freedman, MD³³, Donald W. Bowden, PhD³², Lisa R. Yanek, MPH³⁴, Brian G. Kral, 12 MD, MPH³⁴, Lewis C. Becker, MD³⁴, Patricia A. Peyser, PhD³⁵, Lawrence F. Bielak, DDS, MPH³⁵, 13 Farah Ammous, PhD³⁵, April P. Carson, PhD, MSPH³⁶, Michael E. Hall, MD, MS³⁶, Laura M. 14 Raffield, PhD³⁷, Stephen S. Rich, PhD³⁸, Wendy S. Post, MD³⁹, Russel P. Tracy, PhD⁴⁰, Kent D. 15 Taylor, PhD⁴¹, Xiuging Guo, PhD⁴¹, Michael C. Mahaney, PhD⁴², Joanne E. Curran, PhD⁴², John 16 Blangero, PhD⁴², Shoa L. Clarke, MD, PhD⁴³⁻⁴⁵, Jeffrey W. Haessler, MS⁴⁶, Yao Hu, PhD⁴⁶, 17 Themistocles L. Assimes, MS, PhD⁴³⁻⁴⁵, Charles Kooperberg, PhD⁴⁶, Jürgen Bernhagen, 18 19 PhD^{1,3,51}, Christopher D. Anderson, MD, MMSc^{2,9,10}, Scott M. Damrauer, MD^{7,8,47}, Ramin Zand MD, MPH^{48,49}, Jerome I. Rotter, MD⁴¹, Paul S. de Vries, PhD⁴, Martin Dichgans, MD^{1,3,50,51} 20

21

¹ Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-

- 23 University (LMU), Munich, Germany
- ² Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,
- 25 MA, USA
- ³ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- ⁴ Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental
- 28 Sciences, School of Public Health, The University of Texas Health Science Center at Houston,
- Houston, TX, USA
- ⁵ Department of Molecular and Functional Genomics, Geisinger Health System, Danville,
 Pennsylvania, USA
- 32 ⁶ Veterans Affairs Healthcare System, Boston, MA, USA
- 33 ⁷ Department of Surgery, Perelman School of Medicine at the University of Pennsylvania,
- 34 Philadelphia, PA, USA
- 35 ⁸ Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA

- 36 ⁹Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 37 ¹⁰ Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
- 38 ¹¹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
- ¹² Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical
- 40 Center, Baltimore, MD
- 41 ¹³ The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
- 42 Sinai, New York, NY, USA
- ¹⁴ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New
 York, NY, USA
- 45 ¹⁵ The Center for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ¹⁶ Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New
- 47 York, NY, USA
- 48 ¹⁷ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 49 ¹⁸ Department of Radiology, Vanderbilt University Medical Center, Nashville, TN, USA
- ¹⁹ Cardiovascular Health Research Unit, Department of Medicine, University of Washington,
- 51 Seattle, WA, USA
- ²⁰ Department of Health Systems and Population Health, University of Washington, Seattle, WA,
 USA
- 54 ²¹ Department of Epidemiology, University of Washington, Seattle, WA, USA
- 55 ²² Department of Neurology, University of Washington, Seattle, WA, USA
- ²³ Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora CO,
- 57 USA
- 58 ²⁴ Department of Population Medicine, PRecisiOn Medicine Translational Research (PROMoTeR)
- 59 Center, Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA, USA
- ²⁵ Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston,
- 61 MA, USA
- 62 ²⁶ Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical
- 63 School, Boston, MA, USA
- ²⁷ Department of Biostatistics, University of Washington, Seattle, WA, USA
- ²⁸ Department of Medicine, Boston University School of Medicine, Boston, MA, USA
- ²⁹ Boston University and National Heart, Lung, and Blood Institute's Framingham Heart Study,
- 67 Framingham, MA, USA
- ³⁰ Bigg's Institute for Alzheimer's Disease and neurodegenerative disorders, University of Texas
- 69 Health Science Center, San Antonio, TX, USA
- ³¹ Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA

- 71 ³² Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³³ Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine,
- 73 Winston-Salem, NC, USA
- ³⁴ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ³⁵ Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI,
- 76 USA
- ³⁶ Department of Medicine, University of Mississippi Medical Center, Jackson, MS
- 78 ³⁷ Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
- ³⁸ Center for Public Health Genomics, University of Virginia, Charlottesville, VA USA
- ³⁹ Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine,
 Baltimore, MD USA
- 82 ⁴⁰ Departments of Pathology & Laboratory Medicine, and Biochemistry, Larner College of
- 83 Medicine, University of Vermont, Burlington, VT USA
- ⁴¹ The Institute for Translational Genomics and Population Sciences, Department of Pediatrics,
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA
 USA
- 87 ⁴² Department of Human Genetics and South Texas Diabetes and Obesity Institute, University of
- 88 Texas Rio Grande Valley School of Medicine, Brownsville TX USA
- ⁴³ Department of Medicine (Division of Cardiovascular Medicine), Stanford University School of
- 90 Medicine, Stanford, CA, USA
- 91 ⁴⁴ Stanford Cardiovascular Institute, Stanford, CA, USA
- 92 ⁴⁵ VA Palo Alto Health Care System, Palo Alto, CA, USA
- ⁴⁶ Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle WA 98109 USA
- ⁴⁷ Department of Genetics, Perelman School of Medicine at the University of Pennsylvania,
- 95 Philadelphia, PA, USA
- 96 ⁴⁸ Department of Neurology, Pennsylvania State University, Hershey, Pennsylvania, USA.
- ⁴⁹ Department of Neurology, Neuroscience Institute, Geisinger Health System, Danville, PA, USA
- 98 ⁵⁰ German Centre for Neurodegenerative Diseases (DZNE), Munich, Germany
- 99 ⁵¹ German Centre for Cardiovascular Research (DZHK, Munich), partner site Munich Heart
 100 Alliance, Munich, Germany
- 101
- 102 *equally contributed
- 103
- 104
- 105

106 Address for Correspondence:

Marios K. Georgakis, MD, PhD Clinician-Scientist E-mail: <u>marios.georgakis@med.uni-</u> <u>muenchen.de;</u> <u>mgeorgak@broadinstitute.org</u> Tel: +49-89-4400-46156 Martin Dichgans, MD Director E-mail: <u>martin.dichgans@med.uni-</u> <u>muenchen.de</u>

Tel: +49-89-4400-46019

Institute for Stroke and Dementia Research, Ludwig-Maximilians-University Hospital Feodor-Lynen-Str. 17, 81377 Munich, Germany

107

109 ABSTRACT

110

Background and Aims: Ample evidence links CCL2, a key chemokine governing monocyte
 trafficking, with atherosclerosis. However, it remains unknown whether targeting the CCL2
 receptor CCR2 could provide protection against cardiovascular disease.

114 **Methods:** Computationally predicted damaging (REVEL>0.5) variants within CCR2 were 115 detected in whole-exome-sequencing data from 454,775 UK Biobank participants and tested for 116 association with cardiovascular endpoints in gene-burden tests. Given the key role of CCR2 in 117 monocyte mobilization, variants associated with lower monocyte count were prioritized for 118 experimental validation. The response to CCL2 of human cells transfected with these variants 119 was tested in migration and cAMP assays. Validated loss-of-function variants were tested for 120 association with cardiovascular endpoints, atherosclerosis burden, and vascular risk factors. 121 Significant associations were replicated in six independent datasets (n=1,062,595). 122 Results: Carriers of 45 predicted damaging CCR2 variants were at lower risk of myocardial

123 infarction and coronary artery disease. One of these variants (M249K) was associated with lower

124 monocyte count and decreased signaling and chemoattraction in response to CCL2. While

125 M249K showed no association with conventional vascular risk factors, it was consistently

126 associated with a lower risk of myocardial infarction (Odds Ratio: 0.66 95% Confidence Interval:

127 0.54-0.81,p=6.1x10-5) and coronary artery disease(Odds Ratio: 0.74 95% Confidence Interval:

128 0.62-0.87, p=2.9x10-4) in the UK Biobank and in six replication cohorts. In a phenome-wide

association study, there was no evidence of higher infections risk among M249K carriers.

130 Conclusions: Carriers of an experimentally confirmed loss-of-function CCR2 variant are at a

131 lower lifetime risk of myocardial infarction and coronary artery disease without carrying a higher

132 infection risk. Our findings provide genetic support for the translational potential of CCR2-targeting

as an atheroprotective approach.

134 INTRODUCTION

Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality 135 136 worldwide.¹⁻³ Over 20 years of preclinical research have provided overwhelming evidence for a causal role of inflammation in atherogenesis^{4,5} and recent trials provided proof-of-concept that 137 targeting inflammation can lead to reductions in adverse cardiovascular events.⁶⁻⁸ The 138 139 canakinumab anti-inflammatory thrombosis outcome study (CANTOS) demonstrated that 140 treatment with a monoclonal antibody against IL-1ß lowers risk of recurrent vascular events 141 among individuals with recent myocardial infarction.⁶ The colchicine cardiovascular outcomes trial (COLCOT)⁷ and the low-dose colchicine-2 (LoDoCo2) trial⁸ further showed that colchicine, an 142 143 established drug with widespread inhibitory effects on inflammatory pathways.^{9,10} lowers the risk 144 of recurrent vascular events in patients with coronary artery disease (CAD). Targeting 145 inflammation for atheroprotection must be balanced against the impact on any host defense responses. For example, both canakinumab⁶ and colchicine⁷ were associated with adverse 146 147 effects including fatal infections in the CANTOS and the colchicine trials. While translational 148 efforts have mostly focused on the inflammasome-IL-1β/IL-6 axis,¹¹ evidence from preclinical studies and early-phase clinical trials highlights the promise of alternative cytokines⁵ for the 149 development of a second generation of atherosclerosis-centered anti-inflammatory treatments.⁴ 150

151 CC-motif chemokine ligand 2 (CCL2) is a pivotal inflammatory chemokine regulating monocyte 152 trafficking¹² that has been studied as a potential target in atherosclerosis. Preclinical data suggest 153 that pharmacological targeting of CCL2 or its receptor CCR2 might lower atherosclerosis burden in experimental models.¹³ However, only recently large-scale genetic and epidemiological studies 154 155 have highlighted the relevance of the CCL2/CCR2 pathway in human CVD, calling for clinical 156 translation of strategies targeting this pathway.¹⁴ Prospective observational studies^{15,16} support associations of higher circulating CCL2 levels with ischemic stroke and cardiovascular death, 157 158 whereas Mendelian randomization analyses from population genetic studies^{17,18} show 159 associations with higher risk of ischemic stroke and coronary artery disease. Furthermore, CCL2 160 levels are higher in atherosclerotic lesions from patients with symptomatic carotid stenosis, as 161 compared to asymptomatic disease and are associated with features of plaque vulnerability.¹⁹

Although these studies support a role of the CCL2/CCR2 axis in human atherosclerosis, it remains unclear whether pharmacological intervention in this pathway could lead to atheroprotection in humans. Several molecules targeting CCR2 are currently under development for autoimmune disease, liver disease, and cancer and could be repurposed for prevention of atherosclerotic cardiovascular disease.¹⁴ Studies examining the phenotypic effects of rare genetic variants in population-based studies have been instrumental in predicting the consequences of

pharmacological interventions²⁰⁻²⁴ and might thus serve as a validation step for drug targets under
development.

170 Here, we leveraged whole-exome sequencing (WES) data from 454,775 participants of the 171 population-based UK Biobank (UKB) study to explore whether rare loss-of-function (LoF) variants 172 in the CCR2 gene are associated with cardiovascular disease risk, burden of atherosclerosis, and 173 traditional vascular risk biomarkers. We experimentally confirmed the loss-of-function effects of 174 one variant (M249K) with a frequency of 0.1% and replicated its effects on cardiovascular risk in 175 external population- and hospital-based biobanks. Finally, we performed a phenome-wide association study across two biobanks to explore associations of this damaging variant with the 176 177 risk of infections or other potential safety signals of any CCR2-targeting treatments.

178

179 METHODS

180 Study population

We used data from the UKB, a population-based prospective cohort study of UK residents aged 181 40-69 years recruited between 2006-2010 from 22 assessment centers across the UK.²⁵ This 182 183 analysis was restricted to 454,775 out of 502,419 participants with available whole-exome 184 sequencing data (UKB Exome 450k release from October 2021). Primary and secondary 185 analyses were performed with an updated Functional Equivalence (FE) protocol that retains 186 original quality scores in the CRAM files (referred to as the OQFE protocol). We included only variants that met published criteria²⁶: individual and variant missingness <10%, Hardy Weinberg 187 188 Equilibrium p-value>10⁻¹⁵, minimum read coverage depth of 7 for SNPs and 10 for indels, at least 189 one sample per site passed the allele balance threshold >0.15 for SNPs and 0.20 for indels. We 190 used genotype array data released by the UKB study to assign individuals to continental ancestry 191 super-groups (African (AFR), Hispanic or Latin American (HLA, originally referred to as 'AMR' by 192 the 1000 Genomes Project), East Asian (EAS), European (EUR) and South Asian (SAS)) by 193 projecting each sample onto reference principal components (PCs) calculated from the 1000 194 Genomes reference panel. In brief, we merged our samples with all 1000 Genomes samples and 195 kept only SNPs with MAF>10%, genotype missingness<5%, and Hardy-Weinberg equilibrium test $P < 10^{-5}$ that were common between the two datasets. Following pruning to approximately 196 197 200,000 independent variants, we calculated PCs for the 1000 Genomes samples using flashpca2²⁷ and projected each of the UKB samples onto those PCs. To assign a continental 198 199 ancestry group to each non-1000 Genomes sample, we trained a random forest model using the 200 1000 Genomes PCs and calculated the likelihood of a given sample belonging to each of the five 201 continental ancestry groups. When the likelihood for a given ancestry group was >0.9, the sample

was assigned to that ancestry group. Otherwise, the sample was put into the group
"other/admixed". We included only individuals without evidence of relatedness within the UKB
samples, as defined by a KING cut-off of <0.084.

205

206 Detection of loss-of-function genetic variants in CCR2 and experimental validation

Restricting our analyses to the *CCR2* gene, we detected predicted LoF or damaging missense variants with a MAF<1% in the *CCR2* exonic region and then explored which of those are associated with monocyte count as a functional readout. Variants from WES were annotated as previously described²⁸ using VEP v101.^{29,30} We used the LofTee plugin for predicting LoF variants³¹ and a REVEL cutoff of >0.5 from dbNSFP version 4.0a for predicted damaging missense mutations.

213 We aimed to further restrict our analyses to damaging variants with proven functional effects. One 214 of the key functions of the CCL2 axis is the recruitment of classical monocytes from the bone marrow to the circulation in a CCR2-dependent way.³²⁻³⁴ Consequently, damaging variants in the 215 CCR2 gene would be expected to be associated with a lower monocyte count in the circulation. 216 217 To test associations with the circulating counts of monocytes and other white blood cells (WBC). 218 absolute counts were extracted from the UKB fields 30160 (basophil counts), 30150 (eosinophil 219 counts), 30130 (monocyte counts), 30120 (lymphocyte counts) and 30140 (neutrophil counts). 220 Distributions were visually checked for normal distribution and log-normalized when needed. Associations were tested using regenie v2.2.4.³⁵ For WBC analyses, we used sex, age at blood 221 222 draw, and the first 5 ancestral PCs as covariates. The mixed model parameters were estimated 223 using 200,000 genotyped common variants. Saddle point approximation regression was applied. 224 Genetic variants associated with monocyte count at a false discovery rate (FDR)-corrected p-225 value <0.05 were prioritized for further experimental validation. To test whether the associations 226 are specific for monocyte count, we also tested associations with other WBC counts (basophils, 227 eosinophils, lymphocytes, neutrophils) for each variant.

228 Two predicted damaging CCR2 variants showing a significant association with lower monocyte 229 count were brought forward to experimental testing. The two variants were M249K 230 (3:46358273:T:A) and W165S (3:46358021:G:C, both hg38). First, we tested how human CCR2-231 knockout monocytic THP-1 cells transfected with these variants or wild-type CCR2 respond to 232 chemoattraction by CCL2 using a Transwell migration assay (details in Supplementary 233 Methods). Next, we tested whether M249K-mutant CCR2 (which showed an effect in the 234 migration assay) influences cAMP production in response to CCL2 in transfected human 235 HEK293T cells (details in **Supplementary Methods**).

236 Associations with cardiovascular risk, atherosclerosis burden and vascular risk factors

Focusing on two sets of variants, we then explored associations of CCR2 variants with clinical 237 238 cardiovascular endpoints including myocardial infarction, coronary artery disease, acute ischemic 239 stroke, peripheral artery disease, and abdominal aortic aneurysm using ICD-10- and ICD-9-240 coded diagnoses, OPCS4-coded procedures, self-report, and algorithmically-defined phenotypes 241 provided by the UKB as detailed in **Supplementary Table S1**. As our hypothesis was that these 242 variants would lead to reductions in risk by lowering the lifetime burden of atherosclerosis, we 243 also constructed a combined phenotype of atherosclerosis manifestations in four vascular beds 244 (coronary arteries, cerebrovascular system, peripheral arteries of the extremities, and aortic 245 atherosclerosis). Severe atherosclerosis was defined as presence of clinical manifestations in at 246 least two vascular beds (Supplementary Table S1).

247 We followed two approaches to test associations with these phenotypes: (i) we performed a 248 burden test combining all predicted damaging variants (LoF or REVEL >0.5) within CCR2; (ii) 249 focusing on M249K, the only monocyte-lowering CCR2 variant that was experimentally validated 250 in the migration and cAMP assays, we performed logistic regression analysis adjusted for age, 251 sex, and the first 5 ancestral PCs testing. We included both prevalent and incident endpoints as 252 outcomes in all analyses and used Firth's correction for unbalanced case/control ratios in our 253 logistic regression analysis. To explore whether the associations with cardiovascular risk are 254 mediated through known vascular risk factors, we further tested associations of the damaging 255 genetic variants with the following phenotypes: systolic and diastolic blood pressure, circulating 256 LDL and HDL cholesterol, circulating apolipoprotein B levels, circulating glycated hemoglobin A1c 257 (HbA1c) concentration, body mass index, and C-reactive protein. Individuals under 258 antihypertensive medications were excluded in the analyses for systolic and diastolic blood 259 pressure, individuals under lipid-lowering medications were excluded from the analyses for LDL 260 and HDL cholesterol and apolipoprotein B levels, and individuals under glucose-lowering 261 treatments were excluded from the analyses for HbA1c.

262

263 Validation of M249K CCR2 variant in external datasets and meta-analysis

For external validation, we obtained summary statistics from six different data sources based on a pre-defined protocol: the TransOmics and Precision Medicine Program supported by NHLBI (TOPMed) Program including multiple studies and a trans-ancestry population in the US (n=51,732), the population-based deCODE dataset in Iceland (n=345,992), the hospital-based Penn Medicine Biobank (PMBB, n=43,721), the Million Veteran Programme (MVP, n=438,905), the Geisinger DiscovEHR-MyCode cohort in central and northeastern Pennsylvania (n=145,826),

as well as the hospital-based Mass General Brigham Biobank (MGBB, n=36,419). Specifically, 270 271 we requested data from logistic regression models adjusted for age, sex, race, study-specific 272 variables (e.g. sequencing center) and the first 10 PCs (with the Firth's correction) for the M249K 273 variant. The variant was either assessed by sequencing or directly genotyped in all cohorts. 274 Details about the individual cohorts are provided in **Supplementary Methods**. The derived odds 275 ratios (OR) from the six datasets were meta-analyzed using fixed-effects and random-effects 276 meta-analyses and were subsequently also meta-analyzed with the results from the UKB. We set 277 a significance threshold of p<0.05 in the replication meta-analysis. Heterogeneity was assessed 278 with the I² and the Cochran Q statistic.

279

280 Phenome-wide association study

281 To explore potential adverse effects associated with damaging CCR2 genetic variants, we tested 282 associations of M249K with the full range of clinical phenotypes encoded in the UKB and 283 replicated in an external cohort (Geisinger DiscovEHR-MyCode). We used the Phecode Map 1.2 284 to map UKB ICD10-codes to Phecodes³⁶ using all ICD10 codes (main position, secondary position, death records) from the UKB. We excluded Phecodes with <100 cases and Phecodes 285 286 that are male- or female-specific. Individuals were assigned a case status if >1 ICD10 code was 287 mapped to the respective Phecode. To approximate effect size in a logistic regression framework. 288 we used minor allele carrier status as an independent variable and age at baseline, sex and 5 289 ancestry PCs as covariates. We used Firth's correction for unbalanced case/control ratios in our 290 logistic regression analysis for all results with p<0.05. The results from the two cohorts were meta-291 analyzed using fixed- and random-effects models. Heterogeneity was assessed with the I² and 292 the Cochran Q statistic.

293

294 Ethics and data availability

295 All studies have received ethical approvals from the respective ethical authorities and participants 296 in all studies have provided written informed consent. Data from the UKB are available upon 297 submission and approval of a research proposal. The UKB has institutional review board approval 298 from the Northwest Multi-Center Research Ethics Committee (Manchester, UK). We accessed 299 the data following approval of an application by the UKB Ethics and Governance Council 300 (Application No. 36993 and 2532). Summary results from the external cohorts were obtained 301 following a common pre-defined research protocol to principal investigators of the study and are 302 presented in the figures and supplementary tables. deCODE has been approved by the National

303 Bioethics Committee of Iceland, and the study was conducted in agreement with conditions issued 304 by the Data Protection Authority of Iceland (VSN 14-015). All common research protocols for the 305 TOPMed Program have been approved by the institutional review board at the University of 306 Maryland Baltimore, whereas individual participating studies have obtained ethical approval from 307 their local ethical authorities, as described previously.³⁷ The Penn Medicine BioBank is approved 308 by the University of Pennsylvania, MVP by the Veterans Affairs Central Institutional Review 309 Board, the Geisinger DiscovEHR-MyCode cohort by Geisinger Institutional Review Boards, and 310 MGBB by the Ethics Committee of Mass General Brigham.

311

312 **RESULTS**

313 **Computationally predicted loss-of-function and damaging CCR2 variants**

314 Among 428,191 unrelated (out of 454,775 with whole-exome sequencing data) UK Biobank 315 participants from the whole-exome sequencing data release, we found a total of 45 predicted LoF 316 or damaging (REVEL>0.5) variants in the exonic region of the CCR2 gene distributed across 787 317 heterozygous carriers (frequency 0.18%, Figure 1 and Supplementary Table S2). There was no 318 homozygous carrier of any of these variants and variants were predominantly prevalent in 319 individuals of European ancestry (779 carriers, frequency 0.20%), as compared to individuals of 320 African, Hispanic or Latin American, East Asian, and South Asian ancestry (total of 8 carriers, 321 pooled frequency 0.02%). Due to the very low frequency in other ancestries, we restricted our 322 analyses to individuals of European ancestry (n=393.416), Baseline characteristics of the study 323 population are presented in **Supplementary Table S3**.

324

325 Associations of CCR2 variants with cardiovascular endpoints in gene-burden tests

326 In a discovery analysis including all 45 computationally predicted LoF or damaging variants, we 327 next explored whether genetic variation in CCR2 is associated with atherosclerotic disease using 328 a gene-based burden test. We found nominally significant associations of the predicted damaging 329 CCR2 variants with myocardial infarction (OR: 0.60, 95%CI: 0.40-0.90, p=0.008) and coronary 330 artery disease (OR: 0.76, 95%CI: 0.59-0.99, p=0.03), as well as directionally consistent 331 associations with the odds of all other examined outcomes (ischemic stroke, peripheral artery 332 disease, abdominal aortic aneurysm, Figure 2A). Variant burden was associated with lower risk 333 of a combined atherosclerotic endpoint (OR: 0.80, 95%CI: 0.65-0.98, p=0.03), as well as with 334 severe atherosclerotic disease, defined by clinical manifestations in at least two vascular beds (OR: 0.24, 95%CI: 0.07-0.82 p=0.003; Figure 2B). We found a trend for a dose-response pattern 335

with lower frequency of clinically manifest atherosclerotic disease across the number of vascular

337 beds involved among carriers for these CCR2 variants (frequency of atherosclerosis presence

among carriers vs. non-carriers: in no vascular bed 88.0% vs. 90.7%; in 1 vascular bed 10.5% vs.

339 9.1%; in 2 vascular beds 1.2% vs. 0.3%; in 3 vascular beds 0.3% vs 0.1%, in 4 vascular beds

340 0.03% vs 0%; OR from ordinal regression: 0.74, 95%CI: 0.54-0.97, p=0.01).

341

342 **Functional consequences of CCR2 damaging variants**

343 To move beyond computationally predicted functional effects, we followed a two-step approach

344 to select CCR2 variants with functional relevance. Since one of the key functions of CCL2 is the

345 CCR2-dependent recruitment of classical monocytes from the bone marrow to the circulation, we

346 first tested the association of the predicted damaging variants in CCR2 with circulating monocyte

347 counts. We found two variants (M249K and W165S) to be associated with lower monocyte counts

- 348 FDR-corrected p<0.05, Supplementary Table S2) and prioritized them for experimental
- 349 validation.

350 We tested whether transfection of human CCR2-knockout THP-1 monocytes with either of these

351 two variants influences directed migration towards CCL2 in a trans-migration cell assay. Cells

352 transfected with M249K showed a clearly reduced response to CCL2, when compared to cells

353 transfected with wild-type CCR2, resembling the response of CCR2-knockout cells (Figure 3A

and **Supplementary Figure S1**). Cells transfected with W165S showed a profile similar to cells

355 transfected with wild-type CCR2 (Supplementary Figure S1). HEK293T cells transfected with

356 M249K further showed a profound reduction of cAMP production in response to CCL2, when

357 compared to HEK293T cells transfected with wild-type *CCR*2 (**Figure 3B**).

358 M249K has a frequency of 0.15% among UKB participants of European ancestry and leads to the

359 replacement of methionine by lysine in the sixth transmembrane domain of the CCR2 receptor

360 (Figure 1). Confirming the specificity of the consequences of M249K on monocyte recruitment,

361 we found no evidence of associations with any of the other leukocyte type counts in the UKB

- 362 (Figure 3C).
- 363

364 Associations of M249K with cardiovascular risk and replication in external cohorts

365 Carriers of the M249K variant were at lower risk of myocardial infarction (OR: 0.62 95%CI: 0.40-

366 0.97, p=0.03) and coronary artery disease (OR: 0.73 95%CI: 0.56-0.97, p=0.02) in the UKB

- 367 (Figure 4A). As expected, given that M249K was by far the most frequent among computationally
- 368 predicted damaging CCR2 variants, we found associations with a lower risk of the combined

369 atherosclerosis endpoint, as well as significantly lower risk of severe atherosclerosis 370 (manifestations in ≥2 vascular beds, Figure 4B), similar to the burden test. To explore whether 371 the effects of M249K are mediated through effects on risk factors targeted by current preventive 372 approaches, we next tested associations with established biomarkers of vascular risk. We found 373 no associations with any of the tested vascular risk factors including blood pressure, 374 hyperglycemia, or circulating lipids. Furthermore, there was no evidence of association with the 375 levels of the known inflammatory biomarker C-reactive protein, thus suggesting that the effects 376 might be independent of factors targeted by current atheroprotective anti-inflammatory treatments 377 (Figure 4C). 378 As these associations were only nominally significant and suggestive of an effect of this variant, 379 we aimed to externally replicate our findings to provide robust evidence for an association with a 380 lower risk of myocardial infarction and coronary artery disease. To externally replicate the effects 381 of M249K, we meta-analyzed data from six external datasets (TOPMed, deCODE, PMBB, MGB,

382 MVP, Geisinger). The frequency of the variant varied between the six datasets (range: 0.0006% 383 in MVP to 0.228% in Geisinger), totaling 767 heterozygous carriers among 1,062,595 individuals 384 (91,420 myocardial infarction and 142,361 coronary artery disease cases). When meta-analyzing 385 data from the six cohorts for the association between carrying M249K and risk of myocardial 386 infarction or coronary artery disease, the ORs were comparable to those of the UKB (OR for 387 myocardial infarction: 0.67 95%CI: 0.53-0.85, p=0.0006; OR for coronary artery disease: 0.74 388 95%CI: 0.53-0.85, p=0.003, Supplementary Figure S2 and Supplementary Table S4). When 389 meta-analyzing these data with UKB reaching a sample size of 1,456,011 individuals including 390 1,314 M249K carriers (111,394 and 207,019 cases of myocardial infarction and coronary artery 391 disease, respectively), we found M249K carriers to have 34% lower odds of suffering a myocardial 392 infarction (OR: 0.66 95%CI: 0.54-0.81, $p=6.1\times10^{-5}$) and 26% lower odds of coronary artery

- 393 disease (OR: 0.74 95%CI: 0.62-0.87, p=2.9x10⁻⁴, Figure 4D-E, Supplementary Table S4).
- 394

395 Phenome-wide association study

As a last step, we performed a PheWAS to explore whether M249K is associated with potential adverse effects that would raise signals for possible side-effects of any CCR2-targeting treatments. Because we lacked statistical power for most of the outcomes, we restricted our analyses to endpoints with \geq 10 cases in the carrier group of the UKB. To increase statistical power, we meta-analyzed our results with the Geisinger cohort. Across all phenotypes only myocardial infarction showed an association with M249K that passed the FDR-corrected p<0.05 threshold. Coronary atherosclerosis and angina pectoris were also less frequent (p<0.05) among 403 carriers although only at a nominal non-corrected p<0.05 (Figure 4A). No infectious disease

404 phenotypes were found to be more common (p<0.05) among M249K carriers (**Supplementary**

405 **Table S5**). Senile cataract was more common among carriers (p<0.05). Among UKB participants,

406 we found no evidence for an association between carrier status for a CCR2 damaging variants

- 407 and survival over a 15-year follow-up period (Figure 4B).
- 408

409 **DISCUSSION**

410 Using data from 1.5M individuals we found that heterozygous carriers of a rare experimentally

411 confirmed loss-of-function CCR2 variant (M249K) are at lower lifetime risk of myocardial infarction 412 and coronary artery disease. Carriers of this variant showed no differences in LDL cholesterol, 413 blood pressure, BMI, HbA1c and C-reactive protein levels, indicating that damaging CCR2 414 variants exert their effects independently of conventional vascular risk factors targeted by 415 available atheroprotective treatments. On the other hand, we found no evidence of associations 416 with higher risk of infectious diseases or overall mortality among carriers. Collectively, our results 417 provide genetic support for CCR2 as a potential therapeutic target for atherosclerotic 418 cardiovascular disease.

419 Our findings extend our previous results from a Mendelian randomization study suggesting a 420 higher atherosclerosis risk among individuals with genetic predisposition to elevated CCL2 levels.¹⁷ That study focused on common genetic variants distributed across the genome and 421 422 shown to influence CCL2 levels in trans. In contrast, the current study assessed damaging rare 423 genetic variants within the CCR2 gene. The functional impact of M249K, the most frequent variant 424 among those associated with atherosclerotic disease, was experimentally confirmed. As such, 425 our approach is unlikely to be confounded by pleiotropic effects of the variants. Despite the lack 426 of data from clinical trials targeting CCR2 in patients with cardiovascular disease, studies in 427 experimental models of atherosclerosis have provided supportive evidence for an 428 atheroprotective effect of pharmacologically targeting CCR2.¹³

Our work consistently connects these findings to humans and provides a rationale for conducting a clinical trial with pharmacological targeting of CCR2 in patients with atherosclerosis. Ultimately, only clinical testing can provide evidence in favor of or against pharmacological targeting of CCR2 for patients with atherosclerosis. A major bottleneck for initiating a clinical trial would be the need for proof of concept in a phase 2 trial before a trial with hard endpoint is conducted. Given the evidence that CRP levels are not directly affected by the CCL2/CCR2 axis,¹⁵ an intermediate endpoint is needed that captures plague inflammation, and in particular, macrophage 436 accumulation.¹³ PET imaging, particularly with an FDG tracer, has shown promise for detecting

437 macrophage content in large plaques and has already been used in phase 2 trials targeting plaque

438 inflammation.³⁸⁻⁴⁰ In addition, recent advances in tracer development have enabled the

- 439 development of a tracer that specifically binds to CCR2.⁴¹ Initial data from patients have shown
- 440 promise in imaging monocyte recruitment to the heart following myocardial infarction.⁴¹

441 Interestingly, we found no evidence supporting a connection of M249K with established 442 pharmacological targets of atherosclerosis, such as LDL cholesterol, hyperglycemia, or elevated 443 blood pressure. This implies that any benefit from CCR2-targeting approaches would be expected 444 to be independent of available preventive approaches against atherosclerotic disease. Also, we 445 found no evidence of associations with circulating C-reactive protein levels, a biomarker of the 446 activity of the IL-6 signaling pathway that is also the target of atheroprotective anti-inflammatory 447 treatments currently under development.⁴² Based on this, our findings suggest that CCR2 448 inhibition might have an atheroprotective effect on top of such approaches, which in turn might be 449 an argument to pursue approaches embracing combination therapies.

450 Our PheWAS analysis was limited by low statistical power. Nevertheless, it is noteworthy that we 451 found no evidence for an association of M249K with risk of infections, which is a potential barrier 452 to the use of atheroprotective anti-inflammatory treatments. This is in line with previous early 453 phase clinical trials testing inhibitors of CCR2 for other indications, which also found no important 454 safety concerns.⁴³⁻⁴⁵ Furthermore, we found no evidence of associations with overall survival, 455 minimizing concerns about a significant impact on unknown fatal adverse effects. The reason why 456 we do not see a protective effect on survival despite the effect on risk of myocardial infarction 457 could be related to statistical power and length of follow-up. It is a common observation that 458 medications with strong effects on lowering cardiovascular risk, such as statins, have failed to

459 show survival benefits.

460 Our study has limitations. First, despite leveraging the largest available whole-exome sequencing 461 studies totaling almost 1.5 million individuals, our results for the PheWAS analyses are still limited 462 by low statistical power and should be interpreted cautiously. Given the rarity of the damaging 463 CCR2 variants, any association with rare potential side-effects would ultimately be undetectable 464 in the context of this study. While formal statistical replication is precluded by this power issue, 465 the consistent effect directions and the overall significance of the meta-analysis raise confidence 466 that the identified association is valid. Further, our main results for associations between M249K 467 and myocardial infarction or coronary artery disease failed to reach the formal thresholds of 468 statistical significance for gene-based or variant-based testing (2.7x10⁻⁶ and 5x10⁻⁸, respectively). As such, this result should be interpreted cautiously as suggestive. Genetic analyses with rare 469

470 variants are still underpowered, as also highlighted in recent burden test studies from the UK 471 Biobank, where no gene showed significant associations with either myocardial infarction or 472 ischemic stroke.⁴⁶ Future research should aim to pool additional data as they become available. 473 Second, UK Biobank consists primarily of European individuals, and consequently, we detected 474 damaging CCR2 variants that are predominantly detected in European populations. As such, our 475 results should not be extended to non-European individuals. Third, all analyses are based on 476 individuals heterozygous for the damaging CCR2 variants, as we found no homozygotes for 477 damaging CCR2 variants. While this lack of homozygotes can be fully explained by the frequency 478 of damaging CCR2 variants in the general population, it remains unknown whether homozygous 479 status for damaging CCR2 variants would lead to potentially fatal complications. Fourth, the data 480 from the UKB do not allow a distinction to be made between classical and non-classical 481 monocytes. The available data suggest that CCL2 only acts on classical CCR2+ monocytes in humans or Ly6C^{hi} monocytes in mice. Experimental studies in mice have revealed that Ccr2-482 deficient Ly6C^{hi} monocytes are trapped in the bone marrow and are not mobilized after 483 484 infections.³² Future studies in humans should further explore the impact of the examined 485 mutations on monocytes subtypes. However, it should be noted that inhibition of monocyte 486 recruitment from the circulation into atherosclerotic lesions is the main suspected mechanism by 487 which CCR2 damaging variants act, and the effects of lowering monocyte counts remain to be 488 tested.

In conclusion, we found that heterozygous carriers of a rare damaging *CCR2* variant are at lower lifetime risk of myocardial infarction and coronary artery disease without carrying a higher risk of infections. This provides further genetic support for the concept that pharmacological targeting of CCR2 might be an efficient and viable immunotherapeutic strategy to prevent atherosclerotic cardiovascular disease.

494

495 Conflicts of Interest: SMD receives research support from RenalytixAI and personal fees from 496 Calico Labs, both outside the current work. MEM receives funding from Regeneron 497 Pharmaceutical Inc. unrelated to this work. RD has received research support from AstraZeneca 498 and Goldfinch Bio, not related to this work. BMP serves on the Steering Committee of the Yale 499 Open Data Access Program funded by Johnson & Johnson. CDA has received sponsored 500 research support from Bayer AG, has consulted for ApoPharma, and is a member of the Editorial 501 Board of Neurology. LMR is a consultant for the TOPMed Administrative Coordinating Center 502 (through WeStat). The other authors have nothing to declare.

503

504 Acknowledgements: Marios K. Georgakis is supported with a Walter-Benjamin fellowship (GZ: 505 GE 3461/1-1, ID: 466957018), a clinician-scientist grant from the Munich Cluster for Systems 506 Neurology (EXC 2145 SyNergy, ID 390857198), and an Emmy Noether grant (GZ: GE 3461/2-1, 507 ID 512461526) by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), 508 as well as by the Fritz-Thyssen Foundation (Ref. 10.22.2.024MN) and the Hertie Foundation 509 (Hertie Network of Excellence in Clinical Neuroscience, ID P1230035). Scott M. Damrauer is 510 supported by IK2-CX001780. We acknowledge the Penn Medicine BioBank (PMBB) for providing 511 data and thank the patient-participants of Penn Medicine who consented to participate in this 512 research program. We would also like to thank the Penn Medicine BioBank team and Regeneron 513 Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB 514 protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, 515 a gift from the Smilow family, and the National Center for Advancing Translational Sciences of 516 the National Institutes of Health under CTSA award number UL1TR001878. We thank Geisinger 517 MyCode Community Health Initiative and Geisinger-Regeneron DiscovEHR collaboration 518 contributors who have been critical in the generation of the original data used for this study. This 519 publication does not represent the views of the Department of Veterans Affairs or the United 520 States Government, Paul S. de Vries, Natalie R. Hasbani, and Alanna C. Morrison were supported 521 by R01 HL146860. Joshua C. Bis and Bruce M. Psaty were funded in part by R01HL105756. 522 Reading of the carotid IMT measures was supported by N01HC85085, N01HC45133; Coronary 523 Calcium scans were supported by R01HL64587. Kendra A. Young is supported by NHLBIn U01 524 HL089897 and U01 HL089856. Sharon M. Lutz was supported by R01 MH129337. Nicholette D. 525 Palmer, Barry I. Freedman and Donald W. Bowden were supported by R01 AG058921. Patricia 526 A. Peyser was supported by R01 HL146860. Lawence F. Bielak was supported by R01 527 HL146860. LMR was supported by T32 HL129982 and by the National Center for Advancing 528 Translational Sciences, National Institutes of Health, through Grant KL2TR002490. Christopher 529 D. Anderson receives sponsored research support from the US National Institutes of Health 530 (R01NS103924, U01NS069673), the American Heart Association (AHA 21SFRN812095). Whole 531 genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was 532 supported by the National Heart, Lung and Blood Institute (NHLBI). Cohort-specific 533 acknowledgements for studies included in the TOPMed program are provided in Supplementary Table S6. Jürgen Bernhagen is supported by grants from the Deutsche Forschungsgemeinschaft 534 535 (DFG; CRC 1123 [A3], BE 1977/14-1, and Munich Cluster for Systems Neurology [SyNergy, EXC 2145; ID390857198]. Martin Dichgans is supported by grants from the Deutsche 536 537 Forschungsgemeinschaft (DFG: CRC 1123 [B3], DI-722/16-1 [ID: 428668490], DI-722/21-1, and 538 Munich Cluster for Systems Neurology [SyNergy, EXC 2145; ID390857198]), the Leducq

539 Foundation, the flagship P4-medicine project *DigiMed* Bayern and the Vascular Dementia540 Research Foundation.

544 **REFERENCES**

545

Diseases, G.B.D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries
 and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
 2019. *Lancet* 396, 1204-1222 (2020).

- Guedeney, P., *et al.* Residual Inflammatory Risk in Patients With Low LDL Cholesterol
 Levels Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol* **73**, 2401-2409
 (2019).
- 3. Ridker, P.M. How Common Is Residual Inflammatory Risk? *Circ Res* **120**, 617-619 (2017).
- Lutgens, E., *et al.* Immunotherapy for cardiovascular disease. *Eur Heart J* 40, 3937-3946
 (2019).
- 555 5. Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat*556 *Med* 17, 1410-1422 (2011).
- 557 6. Ridker, P.M., *et al.* Antiinflammatory Therapy with Canakinumab for Atherosclerotic
 558 Disease. *N Engl J Med* **377**, 1119-1131 (2017).
- Tardif, J.C., *et al.* Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *The New England journal of medicine* **381**, 2497-2505 (2019).
- 561 8. Nidorf, S.M., *et al.* Colchicine in Patients with Chronic Coronary Disease. *N Engl J Med*562 383, 1838-1847 (2020).
- 563 9. Leung, Y.Y., Yao Hui, L.L. & Kraus, V.B. Colchicine--Update on mechanisms of action and
 564 therapeutic uses. *Semin Arthritis Rheum* 45, 341-350 (2015).
- 565 10. Opstal, T.S.J., *et al.* Colchicine Attenuates Inflammation Beyond the Inflammasome in
 566 Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy. *Circulation* 142, 1996 567 1998 (2020).
- 11. Ridker, P.M. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream
 To Identify Novel Targets for Atheroprotection. *Circ Res* **118**, 145-156 (2016).
- 570 12. Mackay, C.R. Chemokines: immunology's high impact factors. *Nat Immunol* 2, 95-101
 571 (2001).
- 572 13. Živković, L., Asare, Y., Bernhagen, J., Dichgans, M. & Georgakis, M.K. Pharmacological
 573 Targeting of the CCL2/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical
 574 Studies. *Arteriosclerosis, thrombosis, and vascular biology* 42, e131-e144 (2022).
- 575 14. Georgakis, M.K., Bernhagen, J., Heitman, L.H., Weber, C. & Dichgans, M. Targeting the
 576 CCL2-CCR2 axis for atheroprotection. *Eur Heart J* 43, 1799-1808 (2022).

- 577 15. Georgakis, M.K., *et al.* Circulating Monocyte Chemoattractant Protein-1 and Risk of
 578 Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. *Circ Res*579 **125**, 773-782 (2019).
- 580 16. Georgakis, M.K., *et al.* Association of Circulating Monocyte Chemoattractant Protein-1
 581 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies.
 582 *JAMA Cardiol* 6, 587-592 (2021).
- 583 17. Georgakis, M.K., *et al.* Genetically Determined Levels of Circulating Cytokines and Risk
 584 of Stroke. *Circulation* 139, 256-268 (2019).
- 585 18. Georgakis, M.K., *et al.* Genetic Architecture of Stroke of Undetermined Source: Overlap
 586 with Known Stroke Etiologies and Associations with Modifiable Risk Factors. *Ann Neurol*587 **91**, 640-651 (2022).
- 588 19. Georgakis, M.K., *et al.* Monocyte-Chemoattractant Protein-1 Levels in Human
 589 Atherosclerotic Lesions Associate With Plaque Vulnerability. *Arteriosclerosis, thrombosis,*590 *and vascular biology* 41, 2038-2048 (2021).
- Interleukin-6 Receptor Mendelian Randomisation Analysis, C., *et al.* The interleukin-6
 receptor as a target for prevention of coronary heart disease: a mendelian randomisation
 analysis. *Lancet* **379**, 1214-1224 (2012).
- Cohen, J.C., Boerwinkle, E., Mosley, T.H., Jr. & Hobbs, H.H. Sequence variations in
 PCSK9, low LDL, and protection against coronary heart disease. *The New England journal of medicine* 354, 1264-1272 (2006).
- 597 22. Clarke, R., *et al.* Genetic variants associated with Lp(a) lipoprotein level and coronary
 598 disease. *N Engl J Med* 361, 2518-2528 (2009).
- 599 23. Nioi, P., *et al.* Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease.
 600 *N Engl J Med* 374, 2131-2141 (2016).
- 601 24. Stitziel, N.O., *et al.* ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.
 602 *J Am Coll Cardiol* 69, 2054-2063 (2017).
- Sudlow, C., *et al.* UK biobank: an open access resource for identifying the causes of a
 wide range of complex diseases of middle and old age. *PLoS Med* 12, e1001779 (2015).
- Backman, J.D., *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature* 599, 628-634 (2021).
- Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobankscale genotype datasets. *Bioinformatics* 33, 2776-2778 (2017).
- Malik, R., *et al.* Whole-exome sequencing reveals a role of HTRA1 and EGFL8 in brain
 white matter hyperintensities. *Brain : a journal of neurology* 144, 2670-2682 (2021).
- 611 29. McLaren, W., et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).

- 612 30. Ioannidis, N.M., *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of
 613 Rare Missense Variants. *Am J Hum Genet* **99**, 877-885 (2016).
- 614 31. Karczewski, K.J., *et al.* The mutational constraint spectrum quantified from variation in
 615 141,456 humans. *Nature* 581, 434-443 (2020).
- Serbina, N.V. & Pamer, E.G. Monocyte emigration from bone marrow during bacterial
 infection requires signals mediated by chemokine receptor CCR2. *Nat Immunol* 7, 311317 (2006).
- Tsou, C.L., *et al.* Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone
 marrow and recruitment to inflammatory sites. *J Clin Invest* **117**, 902-909 (2007).
- 34. Shi, C., *et al.* Bone marrow mesenchymal stem and progenitor cells induce monocyte
 emigration in response to circulating toll-like receptor ligands. *Immunity* 34, 590-601
 (2011).
- Mbatchou, J., *et al.* Computationally efficient whole-genome regression for quantitative
 and binary traits. *Nat Genet* 53, 1097-1103 (2021).
- 626 36. Wu, P., *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow
 627 Development and Initial Evaluation. *JMIR Med Inform* 7, e14325 (2019).
- Taliun, D., et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed
 Program. Nature 590, 290-299 (2021).
- Fayad, Z.A., *et al.* Safety and efficacy of dalcetrapib on atherosclerotic disease using novel
 non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. *Lancet* 378,
 1547-1559 (2011).
- Gaztanaga, J., *et al.* A phase 2 randomized, double-blind, placebo-controlled study of the
 effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after
 an acute coronary syndrome. *Atherosclerosis* **240**, 53-60 (2015).
- 40. van Wijk, D.F., *et al.* Nonpharmacological lipoprotein apheresis reduces arterial
 inflammation in familial hypercholesterolemia. *J Am Coll Cardiol* 64, 1418-1426 (2014).
- Liu, Y., *et al.* Association between circulating monocyte subsets and in-stent restenosis
 after coronary stent implantation in patients with ST-elevation myocardial infarction. *Circ*J74, 2585-2591 (2010).
- 641 42. Ridker, P.M., *et al.* IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk
 642 (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet* 397,
 643 2060-2069 (2021).
- Friedman, S.L., *et al.* A randomized, placebo-controlled trial of cenicriviroc for treatment
 of nonalcoholic steatohepatitis with fibrosis. *Hepatology* 67, 1754-1767 (2018).

- de Zeeuw, D., *et al.* The effect of CCR2 inhibitor CCX140-B on residual albuminuria in
 patients with type 2 diabetes and nephropathy: a randomised trial. *Lancet Diabetes Endocrinol* 3, 687-696 (2015).
- 649 45. Vergunst, C.E., *et al.* Modulation of CCR2 in rheumatoid arthritis: a double-blind,
 650 randomized, placebo-controlled clinical trial. *Arthritis Rheum* 58, 1931-1939 (2008).
- 46. Karczewski, K.J., et al. Systematic single-variant and gene-based association testing of
- thousands of phenotypes in 394,841 UK Biobank exomes. *Cell Genom* **2**, 100168 (2022).

653

Figure 1. Damaging CCR2 variants. Domain structure of the CCR2 protein and position of the
predicted loss-of-function (LoF) or missense damaging (REVEL>0.5) variants present in >2 UK
Biobank participants in the CCR2 exonic regions.




Figure 2. Associations of rare computationally predicted damaging *CCR2* variants with risk of atherosclerotic cardiovascular disease in the UK Biobank. Associations of 45 predicted loss-of-function (LoF) or damaging (REVEL>0.5) *CCR2* variants (minimum allele frequency <0.01) in burden tests with (**A**) risk of cardiovascular disease endpoints and (**B**) a combined atherosclerosis endpoint as well as severe clinical atherosclerotic disease defined by manifestations in at least 2 vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of extremities, aorta) among UK Biobank participants of European ancestry. (**C**) Prevalence of clinically manifest atherosclerosis across 4 vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of extremities, aorta) among CCR2 variants. The odds ratio (OR) is derived from ordinal regression adjusted for age, sex, and the first 5 ancestral principal components.




Figure 3. Validation of the loss-of-function effect of M249K (3:46358273:T:A) on CCL2driven monocyte chemotaxis. (**A**) Experimental outline of chemotaxis assay. Transfected CCR2–/– THP-1 cells (marked in green) and non-transfected cells (marked in red) were used in a Transwell chemotaxis assay. The cells that moved to the lower chamber were collected, stained, and quantified using flow cytometry. (**B**) Chemotaxis in response to increasing concentrations of CCL2 for human *CCR2*-knockout monocytic THP-1 cells transfected with the mutant M249K vs. wild-type CCR2, as determined in a trans-well migration assay (comparisons derived from twoway ANOVA, ns: p>0.05, *** p<0.001, ****p<0.0001). (**C**) Results of cyclic AMP (cAMP) assay. Shown is the cAMP activity in HEK293T cells transfected with either empty vector or wild-type or M249K *CCR2* in response to different concentrations of CCL2. Results are presented as "Ratio 665/620 x 10,000" (ratio of fluorescence at 665 nm and 620 nm x 10,000). (**D**) Associations of M249K with counts of different leukocyte populations in the subset of European ancestry participants of the UK Biobank (N=393,838), as derived from linear regression models adjusted for age, sex, and the first 5 ancestral principal components.





Figure 4. Association of the loss-of-function M249K CCR2 variant with lifetime cardiovascular risk. Associations of the M249K CCR2 variant with risk of (A) cardiovascular disease endpoints, (B) a combined atherosclerosis endpoint and severe clinical atherosclerotic disease defined by manifestations in at least 2 vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of extremities, aorta), and (C) conventional vascular risk biomarkers in models adjusted for age, sex, and the first five principal components among UK Biobank participants of European ancestry. HbA1c and C-reactive protein levels are log-transformed for normalization. Fixed-effects and random-effects meta-analysis of the effects of M249K on risk of (D) myocardial infarction and (E) coronary artery disease across 7 population- and hospital-based biobanks. The effects correspond to odds ratios (OR) derived from logistic regression models adjusted for age, sex, and the first 5 ancestral principal components in each biobank.



Study	Cases	Controls		Odd	ds Rati	ο		OR	95%-CI	
UKB	19,974	373,442		-	—			0.62	[0.40; 0.97]	
TOPMed	6,425	45,307			—			0.46	[0.22; 0.97]	
deCODE	25,448	320,544			_			0.73	[0.17; 3.19]	
PMBB	5,653	38,068			-			1.09	[0.47; 2.50]	
MGB	5,575	30,844		-	-			0.45	[0.20; 1.02]	
MVP	39,613	399,292		+	- - -			0.94	[0.61; 1.45]	
Geisinger	8,706	137,120		- +	-			0.56	[0.39; 0.81]	
Fixed effect model	111,394	1,344,617		\diamond	>			0.66	[0.54; 0.81]	
Random effects mod	lel			\diamond	>			0.66	[0.52; 0.84]	
Heterogeneity: $I^2 = 10\%$	p = 0.35				1				• • •	
C <i>Y</i>			0.2	0.5	1	2	5			

Ε

Study	Cases	Controls	Odds Ratio	OR 95%-CI
UKB TOPMed deCODE PMBB MGB MVP Geisinger	46,042 12,467 43,684 9,765 14,368 53,371 27,322	392,652 48,300 306,935 33,956 22,051 266,264 118,507		0.74 [0.55; 0.99] 0.41 [0.22; 0.78] 0.50 [0.13; 1.89] 1.73 [0.72; 4.16] 0.41 [0.18; 0.95] 0.95 [0.64; 1.40] 0.72 [0.55; 0.95]
Fixed effect model Random effects model Heterogeneity: $I^2 = 44\%$	lel	1,118,665	0.2 0.5 1 2 5	0.74 [0.63; 0.87] 0.74 [0.63; 0.87]

Figure 5. Phenome-wide association study of the damaging M249K CCR2 variant and associations with overall survival. (A) Results from a phenome-wide association study in UK Biobank and the Geisinger DiscovEHR-MyCode cohort for the M249K CCR2 variant amongparticipants of European ancestry. Only phecodes with \geq 10 cases in UK Biobank were analyzed. We present the names of phenotypes associated with rare CCR2 variants at p<0.05. Only myocardial infarction reached an FDR-corrected p-value of <0.05. The results are presented as log-Odds Ratios (log-OR). (B) Kaplan-Meier curves for overall survival across 15 years of follow-up among carriers and non-carriers of the M249K CCR2 variant in the European subset of UK Biobank participants.

